EIM
VRCA icon

Essex Investment Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Essex Investment Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,167
Closed -$559K – 512
2019
Q1 		$559K Buy
+5,167
New +$596K 0.08% 252

Other funds holding VRCA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return

Essex Investment Management's VRCA Position: Q2 2019 in Review

Essex Investment Management sold out of Verrica Pharmaceuticals (VRCA) in Q2 2019, closing a stake of 5,167 shares — an estimated $559K sold.

Essex Investment Management first reported a position in VRCA in Q1 2019 and held it in 1 quarter. The position peaked at $559K in Q1 2019. 41 funds tracked by Wall St. Rank hold VRCA as of Q2 2019.

  • Essex Investment Management reported no remaining Verrica Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Essex Investment Management sold 5,167 Verrica Pharmaceuticals shares in Q2 2019, an estimated $559K.
  • Essex Investment Management first reported a position in Verrica Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Essex Investment Management's Verrica Pharmaceuticals position peaked at $559K in Q1 2019.
  • 41 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2019.

Based on Essex Investment Management's 13F filing for Q2 2019, filed 15 Aug 2019.